DK3285756T3 - Formuleringer af l-ornithinphenylacetat - Google Patents
Formuleringer af l-ornithinphenylacetat Download PDFInfo
- Publication number
- DK3285756T3 DK3285756T3 DK16783692.3T DK16783692T DK3285756T3 DK 3285756 T3 DK3285756 T3 DK 3285756T3 DK 16783692 T DK16783692 T DK 16783692T DK 3285756 T3 DK3285756 T3 DK 3285756T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulations
- phenyl acetate
- ornithine phenyl
- ornithine
- acetate
- Prior art date
Links
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150238P | 2015-04-20 | 2015-04-20 | |
| US201562150676P | 2015-04-21 | 2015-04-21 | |
| US201562211619P | 2015-08-28 | 2015-08-28 | |
| US201562255300P | 2015-11-13 | 2015-11-13 | |
| US201662276754P | 2016-01-08 | 2016-01-08 | |
| PCT/US2016/028298 WO2016172112A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3285756T3 true DK3285756T3 (da) | 2023-05-08 |
Family
ID=57144228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16783692.3T DK3285756T3 (da) | 2015-04-20 | 2016-04-19 | Formuleringer af l-ornithinphenylacetat |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160338982A1 (enExample) |
| EP (2) | EP3285756B1 (enExample) |
| JP (2) | JP2018513171A (enExample) |
| KR (1) | KR20180006904A (enExample) |
| CN (2) | CN113599350A (enExample) |
| AU (2) | AU2016252382A1 (enExample) |
| CA (1) | CA2983146C (enExample) |
| DK (1) | DK3285756T3 (enExample) |
| ES (1) | ES2944311T3 (enExample) |
| HK (1) | HK1251149A1 (enExample) |
| MX (2) | MX391167B (enExample) |
| RU (1) | RU2755904C2 (enExample) |
| WO (1) | WO2016172112A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| CN106810464B (zh) | 2009-04-03 | 2019-01-22 | 欧塞拉治疗有限公司 | L-鸟氨酸苯乙酸盐及其制备方法 |
| ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| JP6990170B2 (ja) | 2015-08-18 | 2022-01-12 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| WO2017083758A1 (en) * | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulation of l-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MX389665B (es) | 2017-05-11 | 2025-03-20 | Ocera Therapeutics Inc | Procesos para producir fenilacetato de l-ornitina |
| WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| CA3138914A1 (en) | 2019-05-09 | 2020-11-12 | Ocera Therapeutics, Inc. | Methods of assessing and treating hepatic encephalopathy |
| US12697317B2 (en) | 2019-10-16 | 2026-08-04 | Amalive Limited | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| PT2319581E (pt) * | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| CN106810464B (zh) * | 2009-04-03 | 2019-01-22 | 欧塞拉治疗有限公司 | L-鸟氨酸苯乙酸盐及其制备方法 |
| AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| ES2517340T3 (es) * | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| AU2014250643B2 (en) * | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| EP2625162B1 (en) * | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
-
2016
- 2016-04-19 HK HK18110518.2A patent/HK1251149A1/zh unknown
- 2016-04-19 EP EP16783692.3A patent/EP3285756B1/en active Active
- 2016-04-19 EP EP23157390.8A patent/EP4205735A1/en not_active Withdrawn
- 2016-04-19 CN CN202110931620.7A patent/CN113599350A/zh active Pending
- 2016-04-19 ES ES16783692T patent/ES2944311T3/es active Active
- 2016-04-19 DK DK16783692.3T patent/DK3285756T3/da active
- 2016-04-19 KR KR1020177032260A patent/KR20180006904A/ko not_active Ceased
- 2016-04-19 JP JP2017554815A patent/JP2018513171A/ja active Pending
- 2016-04-19 US US15/133,087 patent/US20160338982A1/en not_active Abandoned
- 2016-04-19 CA CA2983146A patent/CA2983146C/en active Active
- 2016-04-19 AU AU2016252382A patent/AU2016252382A1/en not_active Abandoned
- 2016-04-19 WO PCT/US2016/028298 patent/WO2016172112A1/en not_active Ceased
- 2016-04-19 CN CN201680036045.1A patent/CN107708684A/zh active Pending
- 2016-04-19 MX MX2017013170A patent/MX391167B/es unknown
- 2016-04-19 RU RU2017137643A patent/RU2755904C2/ru active
-
2017
- 2017-10-12 MX MX2022003855A patent/MX2022003855A/es unknown
-
2021
- 2021-02-05 AU AU2021200740A patent/AU2021200740A1/en not_active Abandoned
- 2021-12-22 US US17/559,453 patent/US20220184014A1/en not_active Abandoned
-
2022
- 2022-03-23 JP JP2022046762A patent/JP2022101549A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022003855A (es) | 2023-03-02 |
| JP2018513171A (ja) | 2018-05-24 |
| MX2017013170A (es) | 2018-04-11 |
| US20160338982A1 (en) | 2016-11-24 |
| RU2755904C2 (ru) | 2021-09-22 |
| US20220184014A1 (en) | 2022-06-16 |
| CN107708684A (zh) | 2018-02-16 |
| CA2983146A1 (en) | 2016-10-27 |
| AU2021200740A1 (en) | 2021-03-04 |
| RU2017137643A (ru) | 2019-05-20 |
| CA2983146C (en) | 2023-09-12 |
| EP3285756B1 (en) | 2023-02-22 |
| HK1251149A1 (zh) | 2019-01-25 |
| MX391167B (es) | 2025-03-11 |
| RU2017137643A3 (enExample) | 2019-09-17 |
| CN113599350A (zh) | 2021-11-05 |
| ES2944311T3 (es) | 2023-06-20 |
| EP4205735A1 (en) | 2023-07-05 |
| KR20180006904A (ko) | 2018-01-19 |
| WO2016172112A1 (en) | 2016-10-27 |
| AU2016252382A1 (en) | 2017-11-02 |
| JP2022101549A (ja) | 2022-07-06 |
| EP3285756A4 (en) | 2019-01-23 |
| EP3285756A1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3626081T3 (da) | Pasteuriseret akkermansia til fremme af vægttab | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| SI3769781T1 (sl) | Stabilna formulacija proti-IFNAR1 | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3185853T3 (da) | Inhalerbare pulverformuleringer af alginatoligomerer | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| MA42692A (fr) | Compositions biopharmaceutiques | |
| EP3273950A4 (en) | ADJUVANE COMPOSITIONS AND RELATED METHODS | |
| DK3250182T3 (da) | Dispergible sammensætninger | |
| DK3798222T3 (da) | Krystallinsk form af den frie base af lorlatinib | |
| DK3334726T3 (da) | Plinabulinsammensætninger | |
| DK3474822T3 (da) | Formuleringer af brincidofovir | |
| EP3364945C0 (en) | SOLID FORMULATION | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3943070T3 (da) | Langtidsvirkende formuleringer af bedaquilin | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3697418T3 (da) | Forbedrede formuleringer af bromocriptin |